Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
IMNM Stock Chart & Stats
$19.06
-$0.28(-2.60%)
At close: 4:00 PM EST
$19.06
-$0.28(-2.60%)
Day’s Range― - ―
52-Week Range$5.15 - $20.46
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.26M
Market Cap
$1.81B
Enterprise Value$761.36M
Total Cash (Recent Filing)$272.64M
Total Debt (Recent Filing)$4.01M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Mar 19, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding91,710,270
10 Day Avg. Volume950,839
30 Day Avg. Volume1,262,334
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)3.44
Price to Sales (P/S)68.88
P/FCF Ratio-5.28
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue78.66
Enterprise Value/Gross Profit-18.92
Enterprise Value/Ebitda-3.78
Forecast
1Y Price Target
$24.90Price Target Upside30.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.2
Revenue Forecast (FY)$7.86M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsManagement continues to express confidence and thinks the dataset will be 'great on all the metrics' for Ph 3 RINGSIDE topline results.
Pipeline AdvancementsAnalyst recommends buying Immunome, Inc. stock due to strong pipeline advancements in cancer immunotherapy.
Strategic PartnershipsThe company's recent strategic partnerships are seen as a positive step towards expanding its research and development capabilities.
Bears Say
Cash ReservesThe company has approximately 1.5 years of cash left, which could limit flexibility.
Regulatory ChallengesConcerns are raised about the potential regulatory hurdles Immunome, Inc. may face with upcoming product approvals.
Short InterestShort interest is relatively high at 21.5% of the float.
Immunome News
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $5.15 and its highest was $20.46 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $1.81B.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Mar 19, 2026 which is in 98 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Nov 06, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.566 by -$0.084.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.58.
How many shares outstanding does Immunome have?
Immunome has 91,710,270 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.566. Following the earnings report the stock price went down -1.677%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.90 (30.64% Upside)
$24.90 (30.64% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 223.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.04%
12-Months-Change
Fundamentals
Return on Equity
-93.04%
Trailing 12-Months
Asset Growth
16.54%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunome
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
IMNM Stock 12 Month Forecast
Average Price Target
$24.90
▲(30.64% Upside)
Technical Analysis
Ownership Overview
1.51% Insiders
25.16% Mutual Funds
46.18% Other Institutional Investors
16.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---